Evidence map›Paper›PMID 32314159›Full record

ArticleAnnals of surgical oncology2020

Appropriate Candidates for Salvage Esophagectomy of Initially Unresectable Locally Advanced T4 Esophageal Squamous Cell Carcinoma.

Eisuke Booka, Ryoma Haneda, Kenjiro Ishii, Takeshi Kawakami, Takahiro Tsushima, Hirofumi Yasui, Tsuyoshi Onoe, Hirofumi Ogawa, Yasuhiro Tsubosa

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1.Esophagus : official journal of the Japan Esophageal Society · 2023
    Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Eisuke BookaDivisions of Esophageal Surgery, Shizuoka Cancer Center Hospital, Nagaizumi, Japan.
Ryoma HanedaDivisions of Esophageal Surgery, Shizuoka Cancer Center Hospital, Nagaizumi, Japan.
Kenjiro IshiiDivisions of Esophageal Surgery, Shizuoka Cancer Center Hospital, Nagaizumi, Japan.
Takeshi KawakamiGastrointestinal Oncology, Shizuoka Cancer Center Hospital, Nagaizumi, Japan.
Takahiro TsushimaGastrointestinal Oncology, Shizuoka Cancer Center Hospital, Nagaizumi, Japan.
Hirofumi YasuiGastrointestinal Oncology, Shizuoka Cancer Center Hospital, Nagaizumi, Japan.
Tsuyoshi OnoeRadiation Oncology and Proton Therapy, Shizuoka Cancer Center Hospital, Nagaizumi, Japan.
Hirofumi OgawaRadiation Oncology and Proton Therapy, Shizuoka Cancer Center Hospital, Nagaizumi, Japan.
Yasuhiro TsubosaDivisions of Esophageal Surgery, Shizuoka Cancer Center Hospital, Nagaizumi, Japan. y.tsubosa@scchr.jp.
Shizuoka Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStandard treatment for unresectable locally advanced esophageal cancer is definitive chemoradiotherapy (dCRT). Although salvage esophagectomy is the only curative treatment available following dCRT failure, the appropriate candidates for salvage esophagectomy remain unclear. PATIENTS AND

methodsThree hundred seventeen patients who underwent dCRT from April 2004 to December 2016 were stratified into three study groups-a complete response (CR) group, chemotherapy or best supportive care (BSC) group, and salvage esophagectomy group-and compared. We also investigated the clinical outcomes and prognostic factors of salvage esophagectomy.

resultsSeventy-one patients (22.4%) achieved CR after dCRT, 18 patients (5.7%) underwent salvage esophagectomy, and 228 patients (71.9%) underwent palliative chemotherapy or BSC. The 5-year overall survival (OS) rates of the CR group, salvage esophagectomy group, and chemotherapy or BSC group were 83.0%, 51.6%, and 1.3%, respectively. Salvage esophagectomy recipients had a worse OS rate than CR patients (p < 0.001) but a better OS rate than those in the chemotherapy or BSC group (p < 0.001). Incomplete resection was the only significant variable associated with poor OS on univariate Cox proportional-hazards analysis (hazard ratio: 7.633, 95% confidence interval: 1.692-34.482; p = 0.008). Patients with tumors in the upper thoracic esophagus were more likely to undergo incomplete resection (p = 0.011).

conclusionsPatients who achieve R0 resection are good candidates for salvage esophagectomy regardless of their response to dCRT. Those with upper thoracic esophageal tumors are at risk of incomplete resection; careful attention is required when considering these patients for salvage esophagectomy.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagectomyChemoradiotherapyHumansNeoplasm StagingSalvage TherapyTreatment Outcome

Identifiers

PMID32314159
OpenAlexW3016390911

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.